Login:
 
Lockyer M. SGLT2 inhibitors reduce risk of serious renal events. Practitioner May 2020;264(1837):8-9

SGLT2 inhibitors reduce risk of serious renal events

25 May 2020Pais-up subscribers

A Scandinavian observational study has shown that sodium-glucose co-transporter 2 (SGLT2) inhibitors are associated with a significant reduction in serious renal events compared with dipeptidyl peptidase-4 (DPP-4) inhibitors. The study used Scandinavian disease registry data to compare population outcomes in the general diabetic population rather than selected groups of high-risk patients.

Paid-up subscribersThis article can be accessed only if you are a paid-up subscriber to The Practitioner.

To view current online and print subscription rates, and to contact the subscription department, click Subscribe today .

To buy this article (£25+tax) copy the article citation above and click Buy article